
Tessera Therapeutics Stock
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Sign up today and learn more about Tessera Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Tessera Therapeutics Stock
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
Investors
Flagship Pioneering
Tessera Therapeutics, Indigo, Codiak Biosciences, Rubius Therapeutics, Cygnal Therapeutics
SoftBank
One97, Flipkart, Delhivery, Cruise, OneWeb, Tokopedia, Ola, Rappi, Devoted Health, AUTO1 Group
Funding History
May 2020 | $2.7M |
---|---|
January 2021 | $230M |
April 2022 | $300M |
Management
Co-Founder & Chief Scientific Officer
Jacob Rubens
President and CFO
Howard Liang
Chief Data Officer
Iain McFadyen
Co-Founder, Chief Executive Officer & Board member
Geoffrey von Maltzahn
Press
biospace - Aug, 24 2022
Tessera Therapeutics Expands Leadership and Boardpulse2 - Apr, 29 2022
Biotechnology Company Tessera Therapeutics Raises Over $300 Millionnews - Apr, 22 2022
The Week’s 10 Biggest Funding Rounds: More Musk As The Boring Company Digs Up $675M, Upside Foods Cultivates $400M Roundstartuparound - Apr, 21 2022
Tessera Therapeutics Inks $300M Series Cbiospace - Apr, 19 2022
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platformbusinesswire - Feb, 28 2022
Serotiny and Tessera Therapeutics enter into collaboration to engineer and optimize programmable Gene Writer proteinsendpts - Jul, 14 2021
Tessera Therapeutics taps former BeiGene CFO Howard Liang to join race to CRISPR 3.0zpr - Jul, 14 2021
Leading Gene Writing Company Tessera Therapeutics Announces Pivotal Expansion of Leadership Teamfiercebiotech - Apr, 7 2021
Bluebird's chief medical officer flies the nest to gene writing biotech Tesseraow - Mar, 12 2021
Tessera Rewrites the Genome Script Using Mobile Genetic Elementsift - Jan, 13 2021
Programmable genetics gets more cash as Tessera Therapeutics gets a $230 million infusionfiercebiotech - Jan, 13 2021
Tessera Therapeutics scores $230M to ramp up 'gene writing' tech to cure diseaseEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase